BioCentury | Apr 28, 2017
Emerging Company Profile

Cutting cravings

The former executive team from CV Therapeutics Inc. are treading familiar ground with an addiction program licensed from Gilead Sciences Inc. Newco Amygdala Neurosciences Inc. aims to develop ANS-6673 to treat substance abuse disorders currently...
BC Week In Review | Aug 17, 2015
Clinical News

Vigabatrin: Phase I/II data

Top-line data from an open-label, U.S. Phase I/II trial in 4 Tourrette’s disorder patients who were refractory to all other previous treatments showed that 1 patient receiving twice-daily oral vigabatrin for 8 weeks achieved a...
BC Week In Review | Nov 4, 2013
Clinical News

Sabril vigabatrin regulatory update

H. Lundbeck said FDA approved a label expansion for Sabril vigabatrin to include use as an adjunctive treatment for refractory complex partial seizures in children ages >=10 years who have inadequately responded to several other...
BC Week In Review | Dec 17, 2012
Clinical News

Sabril vigabatrin neurology data

Lundbeck reported 3-year data from its registry of 4,292 patients with refractory complex partial seizures and infantile spasms receiving Sabril. Specifically, 2,339 (55%) patients discontinued Sabril treatment, of which 14 (0.6%) discontinued due to visual...
BC Week In Review | Nov 12, 2012
Clinical News

Vigabatrin: Phase IIb data

Top-line data from the double-blind, U.S. Phase IIb CPP-01005 trial in 207 cocaine addicts showed that CPP-109 missed the primary endpoint of a greater proportion of cocaine-free patients during the last 2 weeks of treatment...
BC Extra | Nov 9, 2012
Clinical News

Catalyst falls on CPP-109 Phase IIb miss

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) fell $0.95 (66%) to $0.50 on Thursday after the company reported that CPP-109 missed the primary endpoint of a greater proportion of cocaine-free patients during the last two weeks of...
BC Week In Review | Oct 1, 2012
Clinical News

Vigabatrin: Phase II started

Catalyst said investigators at the Mount Sinai School of Medicine began an open-label, U.S. Phase I/II trial to evaluate oral CPP-109 twice daily for 8 weeks in about 10 young adults with treatment-refractory Tourette's disorder....
BC Week In Review | Jul 23, 2012
Clinical News

Vigabatrin: Additional Phase II data

Additional data from the double-blind, U.S. Phase II CPP-01004 trial in 186 cocaine addicts showed that twice-daily 1.5 g vigabatrin for 12 weeks did not lead to visual acuity reductions or significant peripheral visual constriction...
BC Week In Review | May 28, 2012
Clinical News

Vigabatrin: Completed Phase IIb enrollment

Catalyst completed enrollment of about 210 cocaine-dependent patients in a double-blind, placebo-controlled, U.S. Phase IIb trial evaluating vigabatrin. Patients will receive twice-daily 1.5 g oral vigabatrin or placebo for 9 weeks. NIH's National Institute on...
BC Week In Review | Apr 16, 2012
Company News

Alfresa Pharma, Sanofi deal

The companies partnered to develop and commercialize epilepsy treatment vigabatrin in Japan to treat children with epilepsia nutans. The irreversible inhibitor of GABA transaminase (GABA T) is marketed as Sabril . Details were not disclosed. Alfresa...
Items per page:
1 - 10 of 78